12 hours ago
Kepler Capital Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
Kepler Capital analyst David Evans maintained a Buy rating on Novo Nordisk (0QIU – Research Report) on June 23 and set a price target of DKK630.00. The company's shares closed last Monday at DKK461.93.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Evans covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Roche Holding AG, and Novartis AG. According to TipRanks, Evans has an average return of -0.1% and a 55.28% success rate on recommended stocks.
Currently, the analyst consensus on Novo Nordisk is a Moderate Buy with an average price target of DKK631.67, a 36.74% upside from current levels. In a report released yesterday, Deutsche Bank also maintained a Buy rating on the stock with a DKK750.00 price target.
The company has a one-year high of DKK1,032.20 and a one-year low of DKK379.70. Currently, Novo Nordisk has an average volume of 1.33M.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0QIU in relation to earlier this year.
